Search clinical trials for: PRS-344/S095012

Total 3591 results

Servier Bio-Innovation LLC
Institut de Recherches Internationales Servier

Recruiting

A Study of PRS-344/S095012 (PD-L1x4-1BB Bispecific Antibody-Anticalin Fusion) in Patients With Solid Tumors

Solid Tumor

Spain, Australia, Belgium, United States
Servier Bio-Innovation LLC
Regeneron Pharmaceuticals; Institut de Recherches Internationales Servier

Not yet recruiting

Phase 1b/2 Platform Study of Select Immunotherapy Combinations in Participants With Advanced Non-small Cell Lung Cancer (NSCLC)

Non-small Cell Lung Cancer (NSCLC)

Hong Kong, United States, Australia
Pieris Pharmaceuticals, Inc.

Completed

PRS-343 in HER2-Positive Solid Tumors

HER2-positive Breast Cancer | HER2-positive Gastric Cancer | HER2-positive Bladder Cancer | HER2-positive Solid Tumor

United States
Institut de Recherches Internationales Servier
ADIR, a Servier Group company

Recruiting

Immuno-positron Emission Tomography Study of 89Zr-S095012 in Patients With Advanced Solid Tumours

Advanced Solid Tumor

Netherlands
Tela Bio Inc
MCRA

Recruiting

A Retrospective Assessment of OviTex PRS (OviTex) (PRS)

Reconstructive Surgical Procedures

United States
Institut de Recherches Internationales Servier

Completed

A Study of Vorasidenib in Participants With Moderate or Mild Hepatic Impairment and Matched Participants With Normal Hepatic Function

Hepatic Impairment

United States
Imperial College London
Aristotle University Of Thessaloniki

Completed

Anti-hypertensive Medication Dosing Regimen in Effective Blood Pressure Control (HARMONY)

Hypertension

Greece, United Kingdom
SamA Pharmaceutical Co., Ltd

Completed

Safety and Efficacy of SA09012 in Asthma

Mild to Moderate Bronchial Asthma

Korea, Republic of
Servier Bio-Innovation LLC
Institut de Recherches Internationales Servier

Recruiting

S095035 in Adult Participants With Advanced or Metastatic Solid Tumors With Deletion of the Methylthioadenosine Phosphorylase (MTAP) Gene

MTAP-deleted Solid Tumors

Australia, United States
Grupo Español de Rehabilitación Multimodal

Unknown

Postoperative Outcomes Within an Enhanced Recovery After Surgery Protocol (POWER2) (POWER2)

Arthroplasty, Replacement, Knee | Arthroplasty, Replacement, Hip

Spain
Institut de Recherches Internationales Servier
ADIR, a Servier Group company

Active, not recruiting

S095029 as Monotherapy and in Combination With Sym021 in Patients With Advanced Solid Tumor Malignancies Followed by an Expansion Part With Triple Combinations in Patients With Metastatic Gastric or Colorectal Cancers

Solid Tumor

United States, Canada
Institut de Recherches Internationales Servier
ADIR, a Servier Group company; Les Laboratoires Servier (L.L.S), Russia

Completed

A Study Comparing the Blood Levels of Both Pegaspargase (S95014) Formulations (Liquid vs Lyophilized) in the Treatment of Paediatric Patients With Acute Lymphoblastic Leukemia (ALL) (ALL)

Acute Lymphoblastic Leukemia

Russian Federation
Servier
Servier Pharmaceuticals, LLC

Available

Vorasidenib Expanded Access Program

Pathologic Processes | Glioma | Neoplasms | Neoplasms by Histologic Type | Neoplasms, Glandular and Epithelial | Recurrence | Disease Attributes | Neoplasms, Germ Cell and Embryonal | Neoplasms, Neuroepithelial | Neuroectodermal Tumors | Neoplasms, Nerve Tissue
Pieris Pharmaceuticals, Inc.

Active, not recruiting

Cinrebafusp Alfa in Combination With Ramucirumab and Paclitaxel in HER2-High Gastric or GEJ Adenocarcinoma and in Combination With Tucatinib in HER2-Low Gastric or GEJ Andenocarinoma

HER2-positive Gastric Cancer

United States, Korea, Republic of
MEI Pharma, Inc.
SCRI Development Innovations, LLC

Completed

Dose Escalation Study of the Safety and Pharmacokinetics of ME-344 Single Agent for Refractory Solid Tumors (ME-344-001)

Solid Tumors

United States
Boston Scientific Corporation

Completed

The Prefyx PPS™ System eRegistry

Stress Urinary Incontinence

United States
Integra LifeSciences Corporation

Recruiting

The SurgiMend PRS Retrospective Study

Reconstructive Surgical Procedures

United Kingdom, Switzerland, Italy
University of the State of Santa Catarina

Completed

Effect of Pre-op Patient Education on Functional Outcomes After TKA

Knee Arthropathy

Brazil
Pieris Pharmaceuticals, Inc.

Completed

PRS-343 in Combination With Atezolizumab in HER2-Positive Solid Tumors

HER2-positive Breast Cancer | HER2-positive Gastric Cancer | HER2-positive Bladder Cancer | HER2-positive Solid Tumor

United States
B.P. Koirala Institute of Health Sciences

Completed

Preoperative Pain Catastrophizing and Its Association With Postoperative Pain After Lower Limb Trauma Surgery

Pain, Postoperative

Nepal
Barretos Cancer Hospital

Completed

Swallowing Intervention During Radiochemotherapy on Head and Neck Cancer (Swallowing-1)

Swallowing Disorders | Head Neck Cancer

Brazil
Ege University

Completed

Effects of Bolus Surfactant Therapy on Peripheral Perfusion Index and Tissue Carbon Monoxide

Respiratory Distress Syndrome

Turkey
Pieris Pharmaceuticals GmbH
FGK Clinical Research GmbH; Nuvisan Pharma Services; EUROCALIN Consortium

Completed

First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PRS-080

Healthy

Germany
Centre for Addiction and Mental Health

Recruiting

Enhancing Frontal Lobes Plasticity in Mild Cognitive Impairment (PAS-MCI)

Mild Cognitive Impairment | Memory Impairment

Canada
MedImmune LLC
AstraZeneca; MedImmune Ltd

Completed

A Study to Assess the Safety and Immunogenicity of the Drug CAT-354 in Healthy Japanese Subjects

Healthy

United States
Global Alliance for TB Drug Development

Terminated

A Multiple Ascending Dose Study With a Dose Formulation Comparison Cohort to Evaluate the Safety, Tolerability, and Pharmacokinetics of TBA-354 in Healthy Adult Subjects

Tuberculosis
Institut de Recherches Internationales Servier
ADIR, a Servier Group company

Recruiting

Calaspargase Pegol in Adults With ALL

Acute Lymphoblastic Leukemia

United States
Pieris Australia Pty Ltd

Completed

Study of a Single Dose of PRS-060 Administered by Oral Inhalation or IV Infusion in Healthy Subjects

Healthy Subjects

Australia
Corvus Pharmaceuticals, Inc.

Completed

Study to Evaluate the Pharmacokinetics of a New Tablet Formulation of CPI-444 in Fed and Fasted Healthy Male and Female Subjects

Healthy Subjects

United States
SWOG Cancer Research Network
National Cancer Institute (NCI)

Recruiting

Study to Test AKR1C3-Activated Prodrug OBI-3424 (OBI-3424) in Patients With Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL)

Refractory T Acute Lymphoblastic Leukemia | Recurrent T Acute Lymphoblastic Leukemia

United States
Pieris Australia Pty Ltd

Completed

Study of Multiple Doses of PRS-060 Administered by Oral Inhalation in Subjects With Mild Asthma

Asthma

Australia
Institut de Recherches Internationales Servier
ADIR, a Servier Group company; Les Laboratoires Servier (L.L.S), Russia

Completed

A Roll-over Study to Provide Continued Treatment With Lyophilized Pegaspargase (S95014) in Pediatric Patients With Acute Lymphoblastic Leukemia (ALL) (ALL)

Acute Lymphoblastic Leukemia

Russian Federation
Adam S. Kibel, MD
National Cancer Institute (NCI)

Recruiting

Polygenic Risk Stratification Combined With mpMRI to Identify Clinically Relevant Prostate Cancer (PRS)

Prostate Cancer | Polygenic Risk Score

United States
Chong Kun Dang Pharmaceutical

Unknown

A Clinical Study to Evaluate the Safety and Pharmacokinetics of CKD-344

Anticoagulant

Korea, Republic of
Pieris Pharmaceuticals GmbH
FGK Clinical Research GmbH

Unknown

Phase Ib Study to Evaluate PRS-080 in Anemic Chronic Kidney Disease Patients

Anemia of Chronic Kidney Disease

Germany
Chong Kun Dang Pharmaceutical

Completed

Clinical Study to Evauate the Pharmacokinetic Profiles and Safety of CKD-348 in Healthy Volunteers

Healthy

Korea, Republic of
Chong Kun Dang Pharmaceutical

Recruiting

A Clinical Study to Evaluate the Safety and Pharmacokinetics of CKD-344 in Healthy Volunteers

Anticoagulant

Korea, Republic of
Boston VA Research Institute, Inc.
VA Boston Healthcare System

Recruiting

The Genomic Medicine at VA Study (GenoVA)

Coronary Artery Disease | Breast Cancer | Colorectal Cancer | Atrial Fibrillation | Type 2 Diabetes | Prostate Cancer

United States
University of Pittsburgh

Completed

Acellular Dermal Matrix in Tissue Expander Breast Reconstruction: A Prospective, Randomized, Clinical Trial Comparing SurgiMend PRS and AlloDerm RTU

Breast Cancer | Mastectomy

United States
Pieris Pharmaceuticals GmbH
FGK Clinical Research GmbH

Completed

Phase 2a Study to Evaluate PRS-080 in Anemic Chronic Kidney Disease Patients

Anemia of Chronic Kidney Disease

Czechia, Germany
Agios Pharmaceuticals, Inc.

Completed

Study to Evaluate the Relative Bioavailability and Safety of the AG-348 Tablet and Capsule Formulations in Healthy Adults

Healthy Volunteers

United States
Stragen France

Completed

First-In-Human PainCart Study for STR-324

Pain

Netherlands
Agios Pharmaceuticals, Inc.

Completed

A Study to Evaluate the Absorption, Distribution, Metabolism, Excretion and Absolute Bioavailability of AG-348 in Healthy Male Participants Following Administration of a Single Oral Dose of [14C]AG-348 and Concomitant Single Intravenous Microdose of [13C6]AG-348

Healthy Volunteers

United States
Mayo Clinic
National Cancer Institute (NCI)

Completed

Bortezomib in Treating Patients With Advanced Myeloproliferative Disorders

Leukemia | Chronic Myeloproliferative Disorders

United States
Istanbul Medipol University Hospital

Completed

Comparison of Different Pain Rating Scales in Patients With Symptomatic Teeth (CoPRS)

Pain | Dental Pain

Turkey
ACADIA Pharmaceuticals Inc.

Completed

Evaluate the Efficacy and Safety of ACP-044 for the Treatment of Acute Postoperative Pain Following Bunionectomy

Acute Postoperative Pain | Bunionectomy

United States
ACADIA Pharmaceuticals Inc.

Terminated

Evaluate the Efficacy and Safety of ACP-044 in Subjects With Pain Associated With Osteoarthritis of the Knee

Osteoarthritis Pain

United States
Memory Pharmaceuticals
Hoffmann-La Roche

Unknown

A Single-Center, Double-Blind (DB) Study of MEM 3454 on P50 Sensory Gating and Mismatch Negativity in Schizophrenia Patients (P50)

Schizophrenia

United States
Pieris Pharmaceuticals GmbH
FGK Clinical Research GmbH

Completed

Study of Angiocal® in Patients With Solid Tumors, Investigating Safety, Tolerability, Blood Concentration of Study Drug

Solid Tumor

Germany
Abbott

Completed

A Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ABT-384 in Elderly Subjects

Healthy

United States

Search clinical trials for: PRS-344/S095012

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Papua New Guinea

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations